TriVascular Technologies — Merger or Acquisition (November 2015)
105 slides from TriVascular Technologies's merger presentation, Nov 20, 2015
Slide 1: Investor Meeting, VEITH Symposium
Filed by Endologix, Inc. Pursuant to Rule 425 Under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of Subject Company: TriVascular Technologies, Inc. Commission File No.: 001-36419 Investor Meeting VEITH Symposium NOVEMBER 19, 2015 CONFIDENTIAL Fil
Slide 2: Safe Harbor
Safe Harbor Endologix and TriVascular will remain separate operational entities until the closing of the proposed merger transaction. Until closing, Endologix will not offer TriVascular products and TriVascular will not offer Endologix products. Forward-Looking Statements This presentation includes
Slide 3: Agenda
Agenda ? Market & Business Update J. McDermott ? Financials & Forecasts V. Mahboob ? EVAS Global Registry A. Holden, M.D. ? Treatment of Complex AAA M. Thompson, M.D. ? TriVascular Ovation D. Minion, M.D. ? Summary J. McDermott ? Q&A
Slide 4: Endologix Vision
Endologix Vision To provide confidence to patients and physicians as the leading global innovator of aortic therapies
Slide 5: \ Ss A ae. ;
|: y Bs I, ¥ \ 4 Ss A ae. ; bah 9 J : Eas bi Pkt ‘
Slide 6: $3.3B AAA Market Opportunity
$3.3B AAA Market Opportunity $3.3B $2.7B $1.0 $0.9 $0.5 Complex AAA $0.3 $0.3 Opportunity Billions Treated – 28% $ $0.3 Traditional AAA $1.5 Opportunity $1.2 Treated – 78% 2015 2020
Slide 7: Only Company with Both EVAR and EVAS Solutions
Only Company with Both EVAR and EVAS Solutions (post merger) Combined portfolio enables physicians to treat the most patients within IFU EVAR EVAS TriVascular Ovation Endologix AFX Endologix Nellix ? Proximal fixation ? Anatomical Fixation ? AAA fixation ? Ultra-low profile ? Preserve bifurcation ?
Slide 8: Optimal Treatment Options for Each AAA Patient
Optimal Treatment Options for Each AAA Patient AAA Anatomy and Prevalence Nellix AFX Ovation STANDARD ANATOMY 40%??? CHALLENGING NECKS Short Necks 36%? Reverse Taper Necks 33%??? Necks w/Thrombus 14%?? Angled Necks (>60°) 9% CHALLENGING ACCESS Ectatic Iliacs 36%? Narrow Distal Aorta 28%?? (<16mm) Sm
Slide 9: Most Comprehensive AAA Product Line
Most Comprehensive AAA Product Line (post merger)
Slide 10: Significant Clinical Evidence To Drive Adoption
Significant Clinical Evidence To Drive Adoption (post merger) 1,699 1,699 1,296 1,296 1,350 1,200 1,041 1,049 4,300+ 579 Patients TriVascular Endologix Endologix Enrolled by OVATION AFX NELLIX 2017 2015 2016 2017 2015 2016 2017 2015 2016 2017 ? IDE/CAP/PAS ? IDEs ? Global Registry ? Global Registry
Slide 11: Expanded Global Sales Force
Expanded Global Sales Force (post merger) ? World-class team of trained sales representatives and clinical specialists? ~200 sales reps, clinical specialists and agents worldwide – 30% increase? Customers in 44 countries across five continents
Slide 12: Key Milestones to Nellix US Approval
Key Milestones to Nellix US Approval* 2016 2017 Dec Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Jan Feb Mar Submit M3 PMA Approval* Submit M2 Presentation of 1 year IDE clinical data Submit M4 *Based upon current timelines and assumptions
Slide 13: Nellix U.S. Physician Training Program
Nellix U.S. Physician Training Program Following PMA approval, plan to train ~50 physicians/month Q1 Q2 Q3 Q4 Q5 Physician Trainee Demographics 50% Loyal ELGX Users 50% New Users
Slide 14: Complex AAA Represents $1.5B Market Opportunity
Complex AAA Represents $1.5B Market Opportunity Ovation Nellix Alto ChEVAS Ability to treat necks <10mm Ability to extend seal zone above renals 1/3 of Complex Patients 2/3 of Complex Patients *Market Size and Penetration Based on Company Estimates
Slide 15: New Product Pipeline Provides Significant Growth Opportunity
New Product Pipeline Provides Significant Growth Opportunity* (Post Merger) 2015 2016 2017 2018 2019 2020 U.S. CHEVAS Europe THORACIC CHEVAS Asia Pacific(Japan)(Japan)(Japan)(China) CHEVAS (Brazil, Argentina) Latin America CHEVAS (Argentina)(Brazil) * Post-merger estimated regulatory approvals
Slide 16: Creating a Leader in Growth and Innovation
Creating a Leader in Growth and Innovation Increased revenue growth Broad AAA product line Expanded global sales force Significant clinical evidence Robust new product pipeline Improved profitability
Slide 17: Financials & Forecast
Financials & Forecast Vaseem Mahboob Chief Financial Officer
Slide 18: Transaction Overview
Transaction Overview ? Aggregate value of $155 million (based on a $10.00 Endologix share price)(3) $6.19 implied stock value of TriVascular shares; value will fluctuate with Endologix share price through closing Transaction ? ~$19 million in cash Terms ~$9 million for intrinsic value of outstanding
Slide 19: Synergy Model
Synergy Model ELGX TRIV NewCo NewCo 2015 2015(3) 2015 Fcst 2020 Fcst Comments Sales $154-$157M $36-39M $190-$196M $425-$480M 20% CAGR(2) Gross Margin %(1) 68% 62% 67% 74% +7 pts Investing at industry R&D % ~25% ~50% ~30% ~12% Standards SG&A % ~70% ~150%+ ~85% ~40% Sales leverage Cash flow positive &
Slide 20: Line Of Sight To Profitability
Line Of Sight To Profitability (*) 2015 Operating Loss(*) 2020 Operating Profit $80 $100 $(40) $(50) ELGX TRIV Low end High end ? Volume leverage & sales force productivity ? Heavy Investments in Sales & Marketing ? R&D investment levels at par with top tier med ? Clinical & R&D initiatives … manage
Slide 21: Key Financial Measures
Key Financial Measures PROFORMA BALANCE SHEET METRICS SHARE COUNTS ($ millions)($ millions) Q3 15 Q4 15 Outstanding Q3 15 Q4 15 Cash & Cash Equivalents 118 210 TRIV 20.4 20.6 Endologix 67.8 68.3 Trade AR 34 36 Inventory 43 41 Weighted Average TRIV 20.3 20.5 All Other Assets 114 115 Endologix 67.6 68
Slide 22: Financial Summary: Key Takeaways
Financial Summary: Key Takeaways ? Fundamentals strong; line of sight to synergies ? Integration execution plans in place, target execution by 2Q/3Q ; experienced team ? Path to cash flow positive year earlier than strat plan ? Goal: Build a business growing 20% with operating leverage
Slide 23: EVAS Global Registry
Andrew Holden, MBChB Auckland City Hospital Auckland, NZ EVAS Global Registry
Slide 24: EVAS FORWARD Global Registry: One Year Outcomes
EVAS FORWARD Global Registry: One Year Outcomes VEITH SYMPOSIUM NOVEMBER 19, 2015
Slide 25: Disclosures and Disclaimers
Disclosures and Disclaimers ? Andrew Holden MBChB, FRANZCR, EBIR – Clinical Investigator for Endologix Inc. – Medical Advisory Board Member for Endologix Inc.
Slide 26: Disclaimers
Disclaimers ? CAUTION: Nellix® EndoVascular Aneurysm Sealing System is an investigational device. Limited by federal (or United States) law to investigational use only. ? Nellix is approved in Europe. For Nellix EndoVascular Aneurysm Sealing System, prior to use, refer to the “Instructions for Use”
Slide 27: EVAS FORWARD Global Registry: Design and Status
EVAS FORWARD Global Registry: Design and Status Total Patients ? Principal Investigators(n=300*) – Andrew Holden, MBChB, Auckland, NZ – Matt Thompson, MD, London, UK Cohort 1 ? 300 patients, 30 centers with five year follow-up(n=200) ? Real-world experience; no prospective screening Cohort 2 of pati
Slide 28: Cohorts
Cohorts Cohort 1 Cohort 2 Cohort 3 Cohort 4 66.9% 13.0% 12.7% 7.4% N=200 N=39 N=38 N=22 Neck Length ? 10mm Neck Length 5 -10mm Neck Length < 5mm rAAA; EVAR revision; Infrarenal Angle ? 60 Infrarenal Angle 61—90 Infrarenal Angle > 90 AUI; Isolated iliac Juxtarenal / Pararenal aneurysm
Slide 29: Baseline Aneurysm and Vascular Characteristics
Baseline Aneurysm and Vascular Characteristics Parameter Neck Length < 5mm Neck Length ? 10mm Neck Length 5 -10mm Infrarenal Angle > 90° Infrarenal Angle ? 60 Infrarenal Angle 61°—90° Juxtarenal—Pararenal Maximum Sac Diameter, mm 59 (55-65) 59 (56-64) 63 (56-70) Neck Length, mm 27 (19-39) 9 (7-18) 5
Slide 30: AAA Complexity across All-Comer Registries
AAA Complexity across All-Comer Registries EVAS Global Registry (n=300) 50% 46% ENGAGE Registry (n=1262) GREAT Registry (n=400) 40% 30% 20% 17% 13% 8% 10% 6% 5% 2% 1.5% n/r 0% 0.1% 0.5% 0.6% n/r 0% Neck Length Conical Neck Angle Chimney Iliac <10mm Neck >60° Procedure diameters >25mm
Slide 31: Major Adverse Events
Major Adverse Events ?30 days 31d – 1yr Classification n=277 n=272 All Cause Death 3 (1.1%) 11 (4.0%) Peri-operative mortality 3 (1.1%) - AAA-related mortality—1 (0.4%)* Renal Failure 0 2(0.7%) Myocardial Infarction 2(0.7%) 1(0.4%) Bowel Ischemia 0 0 Respiratory Failure 2(0.7%) 2(0.7%) Stroke 1(0.4%
Slide 32: Freedom from All Endoleak
Freedom from All Endoleak Through 1 yr 94.5%
Slide 33: Type Ia Endoleak – Most Common Causes
Type Ia Endoleak – Most Common Causes Stent Low stent Misalignment deployment
Slide 34: Transcatheter Embolization Of Type IA Endoleak
Transcatheter Embolization Of Type IA Endoleak
Slide 35: Resolution of Type II Endoleak
Resolution of Type II Endoleak 30d 6mo 1yr
Slide 36: Freedom from Type II Endoleak
Freedom from Type II Endoleak Through 1 yr 98.2% CONFIDENTIAL
Slide 37: Persistent Endoleaks
Persistent Endoleaks At 30 Days At 1 Year N=277 N=269 Endoleak (Total) 1.4% (4) 0.7% (2) Type IA 1.1% (3) 0.4% (1) Type IB — Type II 0.4% (1) 0.4% (1) Type III —
Slide 38: Endoleaks at Year
Endoleaks at 1 Year 12% 9.8% 10% 8% 6% 4% 2% 0.7% 0% EVAS ENGAGE Type 1A, 1B Type II Type III Type IV Undetermined ENGAGE Registry: Verhagen et al. LINC Symposium 2014
Slide 39: Conclusions from Endoleak Data
Conclusions from Endoleak Data The incidence of ? 30 day and 1 year endoleak remains very low The root causes are attributed to procedural factors – Low stent placement, stent misalignment, or no pre-fill Type 1A and 1B endoleak can be effectively treated Higher incidence of ? 30 day Core Laboratory
Slide 40: Freedom from Secondary Intervention
Freedom from Secondary Intervention 1Yr 98.2% Occlusion 1Yr 96.3% Endoleak 1Yr 92.3% All 277 267 264 262 258 256 205 144 74 277 265 260 257 254 252 202 142 75 31 277 261 256 252 249 247 199 140 74 31
Slide 41: Patients with Secondary Interventions through Yr
Patients with Secondary Interventions through 1 Yr 8% OFF IFU 40% 37% 7% 6% 4.5% 5% 5.6% 6.5% 4% 20% 18% 17% 3% 2% 3.2% 1% 1.6% 1.0% 0% 0% EVAS ENGAGE GREAT ?30d 31d- 1yr ENGAGE Registry : Verhagen H. LINC Symposium 2014 GREAT Registry: Verhoeven E. et al. EJVES 2014;48:131-37
Slide 42: Freedom from Aneurysm-Related and All-Cause Mortality
Freedom from Aneurysm-Related and All-Cause Mortality 1 Yr ARM 98.2% 1 Yr ACM 94.8%
Slide 43: Mortality and MI through Year
Mortality and MI through 1 Year EVAS ENGAGE GREAT ASA Class III/IV 64% 52% 63% Cardiac History 55% 53% 39% All Cause Death 5.1% 7.4% 7.0% AAA-related mortality 1.4% 1.5% NR Myocardial Infarction 1.1% 1.8% ENGAGE: Stokmans et al. EJVES 2012 / Broos et al. J Vasc Surg 2015 GREAT: Verhoeven et al. EJVE
Slide 44: All-Cause and Aneurysm-Related Mortality
All-Cause and Aneurysm-Related Mortality EVAS and ENGAGE ARM ACM ENGAGE: Stokmans et al. EJVES 2012;44:369-75
Slide 45: Conclusions – Year Follow Up
Conclusions – 1 Year Follow Up Impressive results in the first-ever prospective, EVAS all-comers clinical study showing durability of repair Low endoleak and reintervention rates in complex patient population Excellent one year aneurysm related and overall survival outcomes Longer follow-up and addi
Slide 46: Treatment of Complex AAA
Prof. Matthew Thompson St. George’s University London, UK Treatment of Complex AAA
Slide 47: EVAS for Complex AAA
EVAS for Complex AAA Matt Thompson St Georges Vascular Institute, London, UK MT 2015
Slide 48: Disclaimers
Disclaimers CAUTION: Nellix® EndoVascular Aneurysm Sealing System is an investigational device. Limited by federal (or United States) law to investigational use only. Nellix is approved in Europe. For Nellix EndoVascular Aneurysm Sealing System, prior to use, refer to the “Instructions for Use” for
Slide 49: Complex AAA: Aneurysms Involving Visceral Segment
Complex AAA: Aneurysms Involving Visceral Segment 14% Suprarenal Type IV TAAA ~36% of 7% No Neck AAA Market <5mm 15% Short Neck <10mm MT 2015
Slide 50: Change in Endovascular Practice SGVI
Change in Endovascular Practice SGVI Neck Length > 15mm Outside Proximal Neck IFU (d/ l) 100% 35% 30% 90% 25% 20% 80% 15% 10% 70% 5% 60% 0% MT 2015
Slide 51: Endovascular Treatment of Juxta-Renal Aneurysms
Endovascular Treatment of Juxta-Renal Aneurysms Large gains in absolute risk reduction High open elective mortality High turn down rate (41%) rAAA mortalty dramatically increased when neck shorter than 15mm MT 2015
Slide 52: EVAR In Challenging Aortic Morphology
EVAR In Challenging Aortic Morphology 70% reintervention rate 5y MT 2015 Karthikesalingam PLOS One 2015 10 (7)
Slide 53: Custom Made Fenestrated Grafts
Custom Made Fenestrated Grafts “Gold standard” at present Technically challenging – good success Significant “turn down” rate (50%) (manufacturing constraints, morphology) Delay to treatment Off shelf fenestrated treat lower proportion with higher technical difficulty Banno et al JVS 2014; 60: 31 MT
Slide 54: Custom Made Fenestrated Grafts – Reintervention and Mortality
Custom Made Fenestrated Grafts – Reintervention and Mortality Mortality Mortality Mortality 2% 7.8% 28% Early reintervention 7% MT 2015 Globalstar Circ 2012; 125: 2707 Patel et al JVS 2015; 62: 319
Slide 55: EVAR and Parallel Grafts for Juxta-Renal AAA
EVAR and Parallel Grafts for Juxta-Renal AAA Near universal applicability Early results better than expected – durability Issue is seal – gutters / endoleaks Pericles Registry – Type 1 2.9% Improved seal with polymer based technology MT 2015 Donas et al Ann Surg 2015; 262: 546
Slide 56: EVAS and Parallel Grafts
EVAS and Parallel Grafts MT 2015 Off label use
Slide 57: Parallel Grafts and EVAS – Current Practice SGVI
Parallel Grafts and EVAS – Current Practice SGVI fEVR / open turndown Plan to increase sealing zone to 2cm – parallel sided aorta Now approaching standard of care Technique evolved Adjunctive stents for parallel grafts crucial MT
Slide 58: Neck 6-25mm
Neck 6-25mm MT 2015 ©: George's ‘VASCULAR INSTITUTE
Slide 59: MT 2015 St George’s
MT 2015 St George’s VASCULAR INSTITUTE
Slide 60: Visceral Stenting/Placement of Protection Balloons/ EVAS
Visceral Stenting/Placement of Protection Balloons/ EVAS MT 2015
Slide 61: MT 2015 St George’s
MT 2015 St George’s
Slide 62: Parallel Grafts and EVAS – SGVI Series (April 2015)
Parallel Grafts and EVAS – SGVI Series (April 2015) 47 patients: 8 (3)/7 (2)/ 32 (1) 3 ruptured AAA / 4 mycotic / 7 EVAR revisions 2 deaths (1 rupture / 1 elective) 3 endoleaks (all resolved with embolisation) 1 limb occlusion / 1 renal stent stenosis MT 2015 DRAFT RESULTS
Slide 63: Validation Work for Parallel Grafts / EVAS
Validation Work for Parallel Grafts / EVAS MT
Slide 64: Validation Work for Parallel Grafts / EVAS
Validation Work for Parallel Grafts / EVAS MT
Slide 65: Post-market registry of the Nellix System with parallel grafts
Post-market registry of the Nellix System with parallel grafts in juxta- renal, opera-renal and supra-renal AAA Retrospective and prospective Open-label, single-arm, no prospective screening 200 patients, up to 10 international centers with 5y F/U Endpoints typical of EVAR therapy in complex AAA MT
Slide 66: Expanded Indications for EVAS
Expanded Indications for EVAS Promising use of new technology – therapeutic gap Theoretical advantages in using polymer based sealing Early results acceptable – approaching first line therapy Proof of concept – testing Long term results and endograft durability MT 2015
Slide 67: TriVascular Ovation
David J. Minion, MD University of Kentucky College of Medicine, Lexington, KY TriVascula Ovation
Slide 68: Ovation Abdominal Stent Graft Platform
Ovation® Abdominal Stent Graft Platform A Paradigm Shift for EVAR
Slide 69: Polymer Technology
Polymer Technology OTHER STENT GRAFT Stent and fabric compressed in ame space within -atheter allows for significant reduction in ‘Any reduction in profile must come trom compromising
Slide 70: Polymer Technology
Polymer Technology “Injectable Architecture” reduces profile while increasing conformability. Sets to the consistency of a pencil eraser Long-term cushion effect on proximal aortic neck
Slide 71: Why is that important?
Why is that important?
Slide 72: Advantages of Polymer Technology
Advantages of Polymer Technology Reduced Profile
Slide 73: Lowest FDA-Approved Profile
Lowest FDA-Approved Profile
Slide 74: The Perils of Access
The Perils of Access
Slide 75: Iliac Rupture
Iliac Rupture
Slide 76: Iliac Avulsion
E lliac Avulsion
Slide 77: Persistent EVAR Challenges
Persistent EVAR Challenges Characteristics of Hostile Narrow Access Vessels Access Anatomy • Narrow (<6mm) • Occluded 5.3 3.2 Tortuous mm mm Calcified • Aneurysmal Access Vessel Tortuosity 40% Patients < 6mm* M2S Database – 43,000 CT Scans 55% Female Patients <6mm** (CHAP) Collaborative effort – 1,0
Slide 78: Abdominal Aortic Aneurysm Repair
Abdominal Aortic Aneurysm Repair Drive to Safely Expand EVAR While Reducing Invasiveness Open Surgical Repair EVAR Surgical Cutdown Percutaneous EVAR Open EVAR Source Day Mortality 4.3% 1.8% New England Journal of Medicine 2010; 362:1863-1871 Journal of Vascular Surgery, March 2010, Turnbull et al;
Slide 79: Advantages of Polymer Technology
Advantages of Polymer Technology Reduced Profile Custom Molded Sealing
Slide 80: Unique Sealing Mechanism
Unique Sealing Mechanism
Slide 81: Why is that important?
Why is that important?
Slide 82: Irregular, Calcified Plaque
Irregular, Calcified Plaque
Slide 83: Standard Stent Graft
Standard Stent Graft
Slide 84: Polymer Sealing Technology
Polymer Sealing Technology
Slide 85: Persistent EVAR Challenges
Persistent EVAR Challenges Characteristics of Hostile Reverse Tapered Necks At Inferior Neck Anatomy Renal Artery Short Aortic Necks At IR + 5 (<15mm) • Reverse Tapered Necks At IR + 13 Calcium • Thrombus • Severe Angulation Calcium/Thrombus lined Necks Large Diameter 48% Patients < 15mm Necks* M2S
Slide 86: Custom Molded Seal
Custom Molded Seal Self Expanding Stent Graft Wire and fabric grafts create discontinuous points of apposition in irregular and/or tapered anatomy Note: FEA simulations illustrate the spectrum of wall apposition from low (blue) to high (red) Ovation Prime Stent Graft Ovation Prime sealing ring creat
Slide 87: Literally “Water-Tight”
Literally “Water-Tight” Colored Water Sealing Ring Ovation Prime graft sealing colored water in clear tube*
Slide 88: Advantages of Polymer Technology
Advantages of Polymer Technology Reduced Profile Custom Molded Sealing Depressurizes the “Neck” (Sealing Zone)
Slide 89: Ovation System Protects the Aortic Neck
Ovation System Protects the Aortic Neck Self expanding stent graft systems exert continual radial force which can lead to neck dilation, device migration, endoleaks and aneurysm rupture Untreated Aneurysm Self Expanding Stent Graft Ovation Stent Graft Blood Pressure Stent Outward Radial Force
Slide 90: Why is that important?
Why is that important?
Slide 91: Late Failure: Standard Stent-Graft
Late Failure: Standard Stent-Graft Years 6 Years
Slide 92: Late Failure: Standard Stent-Graft
Late Failure: Standard Stent-Graft Years 9 Years
Slide 93: Ovation Platform Protects the Aortic Neck
Ovation Platform Protects the Aortic Neck Ovation Global Pivotal study demonstrates encouraging results with stable neck diameter and durable seal through 4 years due to the unique sealing ring technology which creates no chronic outward force and insulates the neck from blood pressure. Aortic Neck
Slide 94: Case Studies Demonstrate Stable Aortic Neck Diameters
Case Studies From Ovation Global Pivotal Trial Demonstrate Stable Aortic Neck Diameters Straightforward No aortic neck growth at 4 years Pre-case Post-30 day Post 4-year Reverse Tapered Neck No aortic neck growth at 2 years Pre-case Post-30 day Post 2-year Heavy Calcification No aortic neck growth a
Slide 95: Clinical Evidence for the Ovation System
Clinical Evidence for the Ovation System
Slide 96: Ovation Global Pivotal Trial
Ovation Global Pivotal Trial Baseline Aortoiliac Mean ± SD Min, Max Characteristics Aortic diameter 13mm below renal artery (mm)1 22.7 ± 3.1 16.6, 32.3 Juxtarenal angle (degrees)1 19.1 ± 13.5 0.0, 60.0 Proximal neck length (mm)2 22.9 ± 12.5 1.0, 50.0 Aortic aneurysm diameter (mm)2 53.6 ± 9.0 37.8, 9
Slide 97: Ovation Global Pivotal Trial results
Ovation Global Pivotal Trial 4 year results of the global pivotal clinical study to evaluate the safety and effectiveness of the TriVascular Ovation Abdominal Stent Graft System. Technical Success1 All N=161 Defined as successful, delivery and deployment of one aortic body and two iliac limbs 100% 0
Slide 98: Clinical Evidence to Validate the Ovation Platform
Clinical Evidence to Validate the Ovation Platform Over 8,000 patients worldwide have been treated Ovation Abdominal Stent Graft platform, with over subjects in a tightly controlled study or registry Patient demographics, anatomical characteristics, procedural characteristics indicate a challenging
Slide 99: Why not use it for everything?
Why not use it for everything?
Slide 100: Eurostar Classification of AAA
Eurostar Classification of AAA
Slide 101: Slide 101
Slide 102: Slide 102
Slide 103: Thank You
Thank You NASDAQ: TRIV www.trivascular.com
Slide 104: Summary
Summary John McDermott Chief Executive Officer
Slide 105: Summary
Summary Most Comprehensive AAA Product Line Robust New Product Pipeline Traditional AAAs, Complex AAAs and Thoracic ~30% Larger Global Sales Force Significant Clinical Evidence Top Tier Forecasted Financial Performance: Revenue CAGR of 20% Gross margins 70%+ EBITDA margin of 20% by 2020
TriVascular Technologies — Merger or Acquisition (November 2015) on 6ix